Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

GomSpace announces outcome of completed rights issue

GomSpace Group AB (publ) ("GomSpace" or the "Company") hereby announces the outcome of the rights issue of new shares resolved by the board of directors on 17 March 2023, with support of the authorisation from the annual general meeting held on 22 April 2022 (the "Rights Issue"). In total, 77,939,396 new shares, corresponding to approximately SEK 101 million or approximately 83 percent of the Rights Issue, have been subscribed for with and without subscription rights of which 41,225,646 new shares have been subscribed for against payment through set-off of the convertible loan of

GomSpace offentliggör utfall i genomförd företrädesemission

GomSpace Group AB (publ) (”GomSpace” eller ”Bolaget”) offentliggör härmed utfallet i den företrädesemission av nya aktier som beslutades av styrelsen den 17 mars 2023 med stöd av bemyndigande från årsstämman den 22 april 2022 (”Företrädesemissionen”). Totalt har 77 939 396 nya aktier, motsvarande cirka 101 MSEK eller cirka 83 procent av Företrädesemissionen, tecknats med och utan stöd av teckningsrätter varav 41 225 646 nya aktier har tecknats mot betalning genom kvittning av det konvertibla lånet om cirka 53,6 MSEK i enlighet med de teckningsåtaganden som beskrivs i det prospekt som

Immedica’s partner OrphanPacific initiates phase 3 trial with glycerol phenylbutyrate for treatment of urea cycle disorders in Japan

Stockholm, April 21 , 2023 - Immedica’s partner OrphanPacific Inc. (Tokyo, Japan) has enrolled the first patient in the phase 3 clinical trial with glycerol phenylbutyrate for the treatment of urea cycle disorders (UCD) in Japan. Immedica’s CEO Anders Edvell commented: “There is a significant medical need for better treatment options for people living with urea cycle disorders around the world. The initiation of this trial is a significant step towards expanding access to glycerol phenylbutyrate for patients in Japan.” This phase 3 clinical trial is planned to enroll 15 pediatric and

UNION therapeutics to participate at Kempen Life Science Conference

Hellerup, Denmark, April 21, 2023 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced participation at the Kempen Life Science Conference on April 25-26, 2023, in Amsterdam.   Contacts Morten Boesen, Chief Financial Officer, UNION therapeutics A/S +45 2381 5487 morten.boesen@uniontherapeutics.com   Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S +45 5385 3044 stj@uniontherapeutics.com   About UNION

Aker Horizons ASA: Minutes of Annual General Meeting

The 2023 Annual General Meeting of Aker Horizons ASA was held today as a digital meeting with online participation.All resolutions were made in accordance with the proposals set out in the meeting notice. Minutes of the meeting are attached and available on https://akerhorizons.com/investors/shareholder-center/annual-general-meeting/. The general meeting elected six shareholder-appointed directors to the board. Øyvind Eriksen and Lone Fønss Schrøder were re-elected in their current positions for a period of two years. Lene Landøy was re-elected as deputy for a period of one year, and

Lantmännen updates MTN programme and publishes Prospectus, 2023

The Board of Directors of Lantmännen ek for ("Lantmännen") has decided to update its Medium Term Note programme (the "MTN programme"). Due to the MTN programme, Lantmännen's Board of Directors has prepared a base prospectus. The Swedish Financial Supervisory Authority has today, 21 April 2023, approved and registered the base prospectus.The MTN programme provides a framework within which Lantmännen can raise loans in SEK or EURO with a maturity of at least one year within a maximum outstanding nominal amount of SEK 3 billion, or the equivalent thereof in euros, at any given time. The

Read original

Invitation to presentation of Q1 2023

Concordia Maritime invites to teleconference/audio transmission on 4 May 2023 at 16.00 CEST. The session will feature a presentation of the Q1 2023 interim report and a Q&A session.If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions. https://ir.financialhearings.com/concordia-maritime-q1-2023 If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the

Norse Atlantic ASA: Mandatory notifications of trade of close associates

21 April 2023: Reference is made to the stock exchange notice by Norse Atlantic ASA (the "Company") on 20 April 2023 regarding the completion of the subsequent offering of 60,000,000 new shares in the Company (the "Subsequent Offering"), at a subscription price of NOK 2.50 per share (the "Offer Price").Vineta Ltd, a company wholly owned by Terje Bodin Larsen, chairperson of the board of directors of the Company, was allocated 200,000 shares in the Subsequent Offering at the Offer Price. Following the transaction, Terje Bodin Larsen and related parties will control 300,000 shares in the

#23-33 Extended evening Trading Hours for ETPs until 22:00 CET

Nordic Growth Market (NGM) is an innovative Stock Exchange that continuously leads the development of the Nordic ETP market. As the first Exchange in the Nordics, NGM is pleased to offer investors extended evening trading hours until 22:00 CET as from May 2, 2023. The change is applicable for NGM’s ETP markets in Sweden, Finland, Norway and Denmark.  Commencing May 2, Post Open is changed to 22:00 CET and Closed is changed to 22:15 CET. Pre Open and start of Continuous Trading will remain unchanged from the current schedule. The evening trading schedule changes in the specified market

ChromoGenics postpones Annual General Meeting and delivery and publication of the Annual Report for 2022

The Board of Directors of ChromoGenics has decided to postpone the Annual General Meeting and the delivery and publication of the Annual Report for 2022.For practical reasons, the Board of Directors of ChromoGenics has decided to postpone the Annual General Meeting until the 27[th] of June 2023 as well as the publication of the Annual Report for 2022 until the 6[th] of June 2023. Previously communicated date for the Annual General Meeting was the 25[th] of May 2023 and the 27[th] of April 2023 for the Annual Report for 2022.

Kallelse till årsstämma i BPC Instruments AB / Notice to the Annual General Meeting in BPC Instruments AB

Aktieägarna i BPC Instruments AB, org.nr. 556687-2460, kallas härmed till årsstämma torsdagen den 25 maj 2023 kl. 16:00, Mobilvägen 4-6 (EATERY-restaurangen på bottenplan), 223 62 Lund och även digitalt via LegiMeet. / The shareholders of BPC Instruments AB, reg.no. 556687-2460, are hereby invited to attend the Annual General Meeting on Thursday, May 25th, 2023 at 4 p.m., Mobilvägen 4-6 (the EATERY restaurant area at ground floor), 223 62 Lund and digitally by LegiMeet.N.B. The English text is an unofficial translation of the notice to the Annual General Meeting in BPC Instruments AB,

Invitation to web presentation of Formpipe’s Q1 report 2023.

Formpipe will publish its interim report for the first quarter 2023 on Wednesday 26 April 2023 at 08:45 (CEST).The same day at 10:00 (CET), Formpipe’s President and CEO Christian Sundin will host a web presentation in English which is webcasted live on: https://www.formpipe.com/en/q12023, where it also will be available on demand shortly afterwards. Following the presentation, Christian Sundin, and Joakim Alfredson CFO, will be available to answer questions. The report and presentation will be available at: www.formpipe.com/en/investors/reports-and-presentations Welcome!

ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 21 April 2023 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ)  ("ExpreS2ion" or the "Company") has today, on 21 April 2023, based on the authorisation from the Annual General Meeting on 25 May 2022,

Wirtek A/S appoints Martin Dommerby Kristiansen as new independent Board Member

PRESS RELEASE21 April 2023   Wirtek A/S, a leading Danish IT consultancy company, announced the appointment of Martin Dommerby Kristiansen as its new independent Board Member. This appointment is in line with Wirtek's commitment to good corporate governance and will be strengthening the Board of Directors with important sales and marketing skills internationally. Martin Dommerby Kristiansen is an accomplished leader with extensive experience in the international software services industry, business strategy, relationship building, advocacy, digital transformation, strategic sales,

NPRO: 1Q 2023 - Increased operating profit, extended lease and first dividend from Nordr

· Revenues for the first quarter were MNOK 266, increasing from MNOK 243 in the same quarter last year. · Operating profit before value adjustments was MNOK 222 for the first quarter, increasing from MNOK 204 in the same quarter last year. · Profit before income tax and value adjustments was MNOK 120 for the first quarter, corresponding to NOK 0.19 per share for the quarter. · Negative fair-value adjustments of the properties and derivatives were NOK 156 million and NOK 12 million respectively for the quarter. · The net loss was NOK 58 million for the first quarter which

DNV Supplements the Tender Offer Document Relating to the Voluntary Recommended Public Cash Tender Offer for all Shares and Stock Options in Nixu

Nixu Corporation, Stock exchange release, April 21, 2023, 1.00 p.m. EETNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THIS TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. The global quality assurance and risk management provider DNV AS (“DNV” or the “Offeror”) has on February 28, 2023, commenced a voluntary recommended public cash tender offer for all the issued and outstanding shares (the “Shares” or, individually, a “Share”)

Decisions of the Annual General Meeting of Solwers Plc and the organizing meeting of the Board of Directors on 21 April 2023

Solwers Plc, Company Release, 21 April 2023, at 13.00 EEST The Annual General Meeting of Solwers Plc was held in Helsinki on 21 April 2023. The Annual General Meeting adopted the financial statements, and the members of the Board of Directors and the CEO were discharged from liability for the financial year 1.1.-31.12.2022. Dividend payment The Annual General Meeting decided that a dividend of EUR 0.073 per share be distributed for the financial year 2022. The dividend will be paid to a shareholder on 5 May 2023 who, on the dividend record date 25 April 2023, is registered in the

Financial Report January – March 2023

Stockholm, Sweden, April 21, 2023(NYSE: ALV and SSE: ALIV.sdb)Q1 2023: Strong sales growthFinancial highlights Q1 2023$2,493 million net sales17% net sales increase21% organic sales increase*5.1% operating margin5.3% adjusted operating margin*$0.86 EPS - 9% decrease$0.90 adjusted EPS* - 99% increase  Full year 2023 indicationsAround 15% organic sales growthAround 1% negative FX effect on net salesAround 8.5%-9.0% adjusted operating marginAround $900 million operating cash flow  Key business developments in the first quarter of 2023 · Sales increased

SOFTSWISS Jackpot Aggregator Teams Up with Lucky Dreams to Power Jackpot Campaigns

SOFTSWISS Jackpot Aggregator,  a multipurpose jackpot solution for increasing player acquisition and retention, has launched a new jackpot campaign for Lucky Dreams online casino. The partnership promises to bring players an exciting opportunity to win big with various jackpots.Being a rising star among online casinos, Lucky Dreams prioritises loyalty to its players. Lucky Dreams operates under the Curacao licence, making crypto payments accessible for players. Beyond that, Lucky Dreams has a wide content hub that includes live casino games,

Aker ASA: Minutes of Annual General Meeting 2023

The Annual General Meeting of Aker ASA was held today as a digital meeting with online participation.All proposals on the agenda were adopted, cf. the notice of the Annual General Meeting that was published on Oslo Stock Exchange on 29 March 2023. It was resolved to distribute a dividend of NOK 15.00 per share for 2022. The dividend is payable to shareholders holding shares in the Company as per 21 April 2023. The shares will be traded ex-dividend on Oslo Stock Exchange from and including 24 April 2023. The dividend will be paid on or about 4 May 2023. The General Meeting also resolved

Interim report first quarter 2023

First quarter 2023 CONTINUED ROBUST PERFORMANCE WITH 18% REVENUE GROWTH Continuing operations · Order intake SEK 34,363 million (30,474) · Order intake growth, at fixed exchange rates 6% · Revenues SEK 30,968 million (24,921) · Revenue growth, at fixed exchange rates 18% · Adjusted EBITA SEK 6,119 million (5,043) · Adjusted EBITA margin 19.8% (20.2) · Adjusted EBIT SEK 5,638 million (4,730) · Adjusted EBIT margin 18.2% (19.0) · Adjusted profit before tax SEK 5,109 million (4,431) · Profit for the period SEK 3,816 million (3,395) · Adjusted profit for

Decisions of the organisational meeting of Alisa Bank Plc Board of Directors

ALISA BANK PLC STOCK EXCHANGE RELEASE 21.4.2023 AT 12:20 PM EESTOn 20 April 2023, the Annual General Meeting elected Markku Pohjola as Chair and Teuvo Salminen as Deputy Chair of the Board of Directors. At the organisational meeting of the Board of Directors 20 April 2023 held after the Annual General Meeting Teuvo Salminen was elected as Chair and Johanna Lamminen, Sami Honkonen and Tero Weckroth as members of the audit committee. Markku Pohjola was elected as Chair and Lea Keinänen and Jorma Pirinen as members of the personnel committee. At its organisational meeting, the Board

There are no items matching the current filter
There are no more items matching the current filter
Back to top